Longitudinal multi-functional analysis identified responses of T cells, B cells, and monocytes as hallmarks of immunotherapy tolerance in patients with merkel cell carcinoma

• Published in: PloS one Vol. 18; no. 11; p. e0293922
• Main Authors: Tao, Quyuan, Du, Jia-xin, Zhang, Shijing, Lin, Wenjia, Luo, Yongxin, Liu, Ying, Zeng, Jingyan, Chen, Xin-lin
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 20.11.2023; Public Library of Science (PLoS)
• Subjects: Analysis; Antigen presentation; Antigens; B cells; Cancer; Carcinoma; Care and treatment; Cell differentiation; Cell proliferation; Cells; Chemotherapy; Complications and side effects; Datasets; Development and progression; Diagnosis; Drug resistance; Dynamic characteristics; Feature selection; Functional analysis; Gene deletion; Gene expression; Gene sequencing; Genes; Health aspects; Immune evasion; Immune system; Immunodeficiency; Immunological tolerance; Immunotherapy; Ligands; Lymphocytes; Lymphocytes B; Lymphocytes T; Major histocompatibility complex; Medical prognosis; Merkel cell carcinoma; Metabolism; Metastasis; Monocytes; Neuroendocrine tumors; Patient outcomes; Patients; Peripheral blood; Ribonucleic acid; RNA; RNA sequencing; Skin; Skin cancer; Subgroups; T cells; Tumors; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0293922

Merkel cell carcinoma (MCC) is a neuroendocrine carcinoma originating in the skin. Studies are needed to determine the mechanisms of immune escape in patients with MCC, and malignant cell conditions that promote immune evasion. We used Single-cell RNA sequencing (scRNA-seq) to determine cellular features associated with MCC disease trajectory. A longitudinal multi-omics study was performed using scRNA-seq data of peripheral blood harvested from four-time points. Six major cell types and fifteen cell subgroups were identified and confirmed their presence by expression of characteristic markers. The expression patterns and specific changes of different cells at different time points were investigated. Subsequently, bulk RNA data was used to validate key findings. The dynamic characteristics of the cells were identified during the critical period between benign improvement and acquisition of resistance. Combined with the results of the validation cohort, the resistance program expressed in the relapse stage is mainly associated with T cell exhaustion and immune cell crosstalk disorder. Coinciding with immune escape, we also identified a decrease non-classical monocytes and an expansion of classical monocytes with features of high inflammation and immune deficiency. Changes in cellular status, such as depletion of T cells and dysregulation of B cell proliferation and differentiation, may lead to drug resistance in MCC patients. Meanwhile, the widespread decreased antigen presentation ability and immune disorders caused by deletion of MHC class II gene expression should not be ignored.